Dr Reddy’s shares dropped about 2% after Goldman Sachs downgraded the stock and Citigroup turned cautious. Brokerages pointed to limited growth visibility, pipeline concerns, and valuation risks, alongside generics pricing pressure. Citi also flagged muted near-term opportunities in semaglutide, prompting analysts to warn that downside risks may persist despite earlier optimism.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
